You are here: Industry Insights > Kymera Therapeutics

News List

Kymera Therapeutics Announces Proposed Public Offering of Common Stock firstwordpharma
June 29, 2021
Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All of the shares are being offered by Kymera.
Kymera Therapeutics, Sanofi collaborate to advance novel protein degrader therapies to patients pharmaceutical-business-review
July 15, 2020
Kymera Therapeutics announced the company has entered into a multi-program strategic collaboration with Sanofi to develop and commercialise first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases.
Sanofi partners with Kymera in $2bn protein degrader therapies deal pharmaceutical-technology
July 10, 2020
Sanofi has formed a multi-programme collaboration with biotechnology firm Kymera Therapeutics to develop and commercialise protein degrader therapies that target IRAK4 in immune-inflammatory diseases.
Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology firstwordpharma
November 14, 2018
CAMBRIDGE, Mass., Nov. 13, 2018 /PRNewswire/ -- Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough
Kymera Therapeutics Appoints Chief Medical Officer americanpharmaceuticalreview
September 21, 2018
Kymera Therapeutics announced the appointment of Jared Gollob, MD, to the role of Chief Medical Officer. Formerly Vice President of Clinical Development and Global Vice President of Medical Affairs at Alnylam Pharmaceuticals, Dr. Gollob joins to build and